

Akzo Nobel share buyback program (week 25)

Arnhem, the Netherlands, June 25, 2007 — Akzo Nobel (Euronext Amsterdam: AKZ; Nasdaq: AKZOY) has announced that, in line with the launch of its EUR 1.6 billion share buyback program on May 3, 2007, the company has repurchased 1,150,300 common shares in the period June 18 until June 22, 2007. Shares were repurchased at an average price of EUR 62.23 for a total amount of EUR 71.6 million. For detailed information on the daily repurchased shares, see the Akzo Nobel website at www.akzonobel.com/com/Investor+Relations/Financial+FAQ.

The total number of shares repurchased under this program to date is 8,788,800 common shares for a total consideration of EUR 528.2 million.

The completion of the share buyback program is expected by the end of 2007.

- - -

Note to editors

Akzo Nobel is a Fortune Global 500 company and is listed on both the Euronext Amsterdam and NASDAQ stock exchanges. It is also included on the Dow Jones Sustainability Indexes and FTSE4Good Index. Based in the Netherlands, we are a multicultural organization serving customers throughout the world with coatings, chemicals and human and animal healthcare products. We employ around 62,000 people and conduct our activities in these four segments, with operating subsidiaries in more than 80 countries. Consolidated revenues for 2006 totaled EUR 13.7 billion. The financial results for the second quarter will be published on July 24, 2007.

Internet: www.akzonobel.com

Not for publication – for more information

Akzo Nobel nv
Corporate Media Relations, tel. +31 26 366 43 43
Contact: Tim van der Zanden

Safe Harbor Statement*

This press release may contain statements which address such key issues as Akzo Nobel's growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, progress of drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more comprehensive discussion of the risk factors affecting our business please see our Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the company's corporate website www.akzonobel.com. The 2006 Annual Report on Form 20-F will be available at the end of the second quarter of 2007.

* Pursuant to the U.S. Private Securities Litigation Reform Act 1995.